ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
January 28, 2022BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs and Oslo University Hospital announced today... -
BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC)
November 10, 2021BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces that the U.S. Food... -
First patient dosed in bemcentinib COVID-19 trial
June 04, 2020Dosing has commenced in the UK Government-backed Phase II clinical trial assessing BerGenBio's bemcentinib in hospitalised COVID-19 patients.
Pharma Sources Insight January 2025
